Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
Saved in:
| Title: | Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. |
|---|---|
| Authors: | Michalak W; Novo Nordisk Inc., Plainsboro, New Jersey, USA., Bøg M; Novo Nordisk A/S, Søborg, Denmark., Bendixen T; Novo Nordisk A/S, Søborg, Denmark., Chowdhury R; Petauri Evidence, Bicester, UK., Cowley P; Petauri Evidence, Bicester, UK., Laugesen C; Novo Nordisk A/S, Søborg, Denmark., Rathor N; Novo Nordisk A/S, Søborg, Denmark., Kushner RF; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2026 Aug; Vol. 28 (8), pp. 7247-7256. Date of Electronic Publication: 2026 Jun 01. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1463-1326 |
|---|---|
| DOI: | 10.1111/dom.70919 |
